Derivatives aminomethylpropanol acid and pharmaceutical compositions on their basis
The invention relates to new derivatives aminomethylpropanol acid formula 1
where Z represents (CH2)n, O or S; n is 0, 1 or 2; X represents 1-3 substituent, independently selected from hydrogen, halogen, (C1-6)alkyloxy,(C3-6)cycloalkane, (C6-12)aryloxy, (C6-12)aryl, teinila, CN, R6and (C1-4)alkyl, optionally substituted with halogen, or 2 substituent in adjacent positions together represent a condensed (C5-6)aryl group, or O-(CH2)m-O, where m is 1 or 2; Y is 1-3 selected from hydrogen, halogen, (C1-4)alkyloxy and (C1-4)alkyl, optionally substituted with halogen; R1represents COOR7; R2and R6are (C1-4)alkyl; R3, R4and R5independently represent hydrogen; R7, R8and R9independently represent hydrogen or (C1-4)alkyl; or pharmaceutically acceptable salts, and pharmaceutical compositions on their basis, with effect on the Central nervous system. The technical result is to provide new compounds having cannom (see the graphical part)to
Claims
1. Derivatives aminomethylpropanol acid having a General formula I
where Z represents (CH2)n, O or S;n = 0,1 or 2;X represents 1-3 substituent, independently selected from hydrogen, halogen, (C1-6)alkyloxy, (C3-6)cycloalkane, (C6-12)aryloxy, (C6-12)aryl, teinila, CN, COOR6and (C1-4)alkyl, optionally substituted with halogen, or two of the substituent in adjacent positions together represent a condensed (C5-6)aryl group, or O-(CH2)m-O, where m = 1 or 2;Y is 1-3 substituent, independently selected from hydrogen, halogen, (C1-4)alkyloxy and (C1-4)alkyl, optionally substituted with halogen;R1represents COOR7;R2and R6are (C1-4)alkyl;R3, R4and R5independently represent hydrogen;R7, R8and R9independently represent hydrogen or (C1-4)alkyl;or their pharmaceutically acceptable salts.2. Derived aminomethylpropanol acid under item 1, in which Z pre represents methyl.4. Derived aminomethylpropanol acid according to any one of paragraphs.1-4, having a CIS-configuration.5. Derived aminomethylpropanol acid on p. 1, selected from the following levogyrate enantiomers:(-)-lithium CIS-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylpyrrolidine;(-)-sodium CIS-N-methyl-N-(6-methyl-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylpyrrolidine;(-)-sodium CIS-N-methyl-N-(6-phenoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylpyrrolidine;(-)-Li N-methyl-N-[1-(4-forfinal)-6-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl] aminomethylpyrrolidine and(-)-lithium CIS-N-methyl-1N-[1-phenyl-6-(2,2-dimethylpropyl-hydroxy)-1,2,3,4-tetrahydronaphthalen-2-ylmethyl]aminomethylpyrrolidine.6. Derivatives aminomethylpropanol acid of the formula I or their pharmaceutically acceptable salts according to any one of paragraphs.1-5 as an active ingredient of the medicinal product, with effect on the Central nervous system.7. Pharmaceutical composition having an effect on the Central nervous system containing the derived aminomethylpropanol acid of General formula I or its pharmaceutically acceptable salt in a mixture with a pharmaceutically acceptable auxiliary
Same patents:
The invention relates to new N-phenylamine and N-pyridylamine derivative of the formula I
< / BR>in which X denotes O or S;
R1and R2which may be identical or different, denote hydrogen, (C1-C6)alkyl or (C3-C8)cycloalkyl or R1and R2together with the carbon atom to which they are attached, form a (C3-C8)cycloalkyl;
R3means (C6-C12)aryl, optionally substituted by one or more radicals Y, which may be the same or different;
Y represents halogen;
R4and R5represent hydrogen;
Ar denotes one of the following groups or WITH:
< / BR>T represents hydrogen or (C1-C6)alkyl;
T3and T4which may be identical or different, denote (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)allylthiourea;
R6and R7each denotes hydrogen or R6and R7together represent a bond;
Z denotes either (I) the divalent group-CHR9- in which the R11-, in which R10and R11together they form a bond that Z represents the group-CH=CH-, or R10and R11that may be the same or different, have the meanings indicated above for R9or (III) a divalent group-CHR12-CHR13-CH2-, in which R12and R13together they form a bond, Z represents-CH=CH-CH2-, or R12and R13that may be the same or different, have the meanings indicated above for R9,
as well as their additive salts with pharmaceutically acceptable acids or bases, and method of production thereof, pharmaceutical compositions and drug manifesting gipolipedimecescoe and antiatherosclerotic action based on them
< / BR>in which X denotes O or S;R1and R2which may be identical or different, denote hydrogen, (C1-C6)alkyl or (C3-C8)cycloalkyl or R1and R2together with the carbon atom to which they are attached, form a (C3-C8)cycloalkyl;
R3means (C6-C12)aryl, optionally substituted by one or more radicals Y, which may be the same or different;
Y represents halogen;
R4and R5represent hydrogen;
Ar denotes one of the following groups or WITH:
< / BR>T represents hydrogen or (C1-C6)alkyl;T3and T4which may be identical or different, denote (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)allylthiourea;
R6and R7each denotes hydrogen or R6and R7together represent a bond;
Z denotes either (I) the divalent group-CHR9- in which the R11-, in which R10and R11together they form a bond that Z represents the group-CH=CH-, or R10and R11that may be the same or different, have the meanings indicated above for R9or (III) a divalent group-CHR12-CHR13-CH2-, in which R12and R13together they form a bond, Z represents-CH=CH-CH2-, or R12and R13that may be the same or different, have the meanings indicated above for R9,
as well as their additive salts with pharmaceutically acceptable acids or bases, and method of production thereof, pharmaceutical compositions and drug manifesting gipolipedimecescoe and antiatherosclerotic action based on them
The invention relates to novim retinoid compounds of General formula I, II, III, IV with retinoid negative hormone biological activity and/or activity of antagonist retinoids, compositions based on them, a method of determining the retinoid antagonists hormones,the method of treating a pathological state in a mammal, vospriimchivosti to treatment with retinoid antagonist or negative hormone by injection of compound I or II
The invention relates to new compounds of the formula (I)
< / BR>where AG represents a radical selected from formulas (a) and (b) below:
< / BR>R1represents a halogen atom, -CH3CH2OR SIG7, -OR SIG7, СОR8, R2and R3taken together form a 5 - or 6-membered ring, R4and R5represent H, a halogen atom, a C1-C10-alkyl, R7represents H, R8represents H or
X represents the radical-Y-
C-, r' and r" is H, C1-C10alkyl, phenyl, Y represents S(O)nor SE, n = 0, 1, or 2, and salts of compounds of formula (I)
< / BR>where AG represents a radical selected from formulas (a) and (b) below:< / BR>R1represents a halogen atom, -CH3CH2OR SIG7, -OR SIG7, СОR8, R2and R3taken together form a 5 - or 6-membered ring, R4and R5represent H, a halogen atom, a C1-C10-alkyl, R7represents H, R8represents H orX represents the radical-Y-C-, r' and r" is H, C1-C10alkyl, phenyl, Y represents S(O)nor SE, n = 0, 1, or 2, and salts of compounds of formula (I)
The invention relates to new Bermatingen compounds, the United propylenebis communication, General formula I where Ar represents a radical of formula (a) or (b), R1is-OR6or-COR7, R2represents a polyether radical, comprising 1 to 6 carbon atoms and 1 to 3 atoms of oxygen or sulfur, and if in the latter case, R4represents a linear or branched C1-C20alkyl, he is in ortho - or meta-position relative to X-Ar connection, R3represents lower alkyl, or R2or R3taken together form a 6-membered ring, optionally substituted by at least one of the stands and/or optional split the atom of oxygen or sulfur, R4represents H, linear or branched C1-C20alkyl or aryl, R5represents H or-OR8, R6represents H, R7represents H, -OR10or-N(r)r (r) r are H, lower alkyl or taken together with the nitrogen atom form a ring of morpholino, R8represents H or lower alkyl, R10represents H, linear or branched C1-C20alkyl, X represents a divalent radical, which is from right to left or Vice versa has the formula (d), R11Fri carboxylic acid and the optical and geometrical isomers of the above compounds of formula (I)
The invention relates to new compounds with retinopathy biological activity
The invention relates to new heterocyclic condensed to benzoylpyridine General formula I, where R1and R2denote independently from each other H or A; X denotes CR4R5; C=Z or O, Y represents CR6R7Z denotes O or CH2, R4, R5, R6or R7denote independently from each other H, A, HE or OA, or R5and R6or R7and R8indicate link together, with each molecule may receive a maximum of only one such bond, or R4and R5indicate together O-(CH2)2-O or O-(CH2)3-O, or R8and R9denote independently from each other H or A; And denotes alkyl with 1 to 6 C-atoms; n represents 0 or 1, and their physiologically acceptable salts
The invention relates to non-steroidal anti-inflammatory drugs, particularly to substituted dihydrobenzofuran and related compounds
Derivatives chromane, intermediate compounds, pharmaceutical composition and methods of treatment. // 2223269
The invention relates to new derivatives chromane General formula I,
,
where R is hydrogen, halide or NR1R1group; R1means hydrogen or alkyl group with 1-10 carbon atoms; R2means R1or NR1R1; R3means hydrogen or CO2R1; Ar1means a phenyl group or a 5-or 6-membered heterocyclic ring containing as the heteroatom atom N; m = 1, 2, or 3; n = 1, when this symbol is the group -(CO)nand n is 0, 1 or 2, when this symbol is the group (X); X is alkyl group with 1-4 carbon atoms; R4means hydroxyl or CNS group with 1-10 carbon atoms; and their pharmaceutically acceptable salts, having agonistic activity against beta-3-adrenergic receptor
,where R is hydrogen, halide or NR1R1group; R1means hydrogen or alkyl group with 1-10 carbon atoms; R2means R1or NR1R1; R3means hydrogen or CO2R1; Ar1means a phenyl group or a 5-or 6-membered heterocyclic ring containing as the heteroatom atom N; m = 1, 2, or 3; n = 1, when this symbol is the group -(CO)nand n is 0, 1 or 2, when this symbol is the group (X); X is alkyl group with 1-4 carbon atoms; R4means hydroxyl or CNS group with 1-10 carbon atoms; and their pharmaceutically acceptable salts, having agonistic activity against beta-3-adrenergic receptor
The invention relates to new N-phenylamine and N-pyridylamine derivative of the formula I
< / BR>in which X denotes O or S;
R1and R2which may be identical or different, denote hydrogen, (C1-C6)alkyl or (C3-C8)cycloalkyl or R1and R2together with the carbon atom to which they are attached, form a (C3-C8)cycloalkyl;
R3means (C6-C12)aryl, optionally substituted by one or more radicals Y, which may be the same or different;
Y represents halogen;
R4and R5represent hydrogen;
Ar denotes one of the following groups or WITH:
< / BR>T represents hydrogen or (C1-C6)alkyl;
T3and T4which may be identical or different, denote (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)allylthiourea;
R6and R7each denotes hydrogen or R6and R7together represent a bond;
Z denotes either (I) the divalent group-CHR9- in which the R11-, in which R10and R11together they form a bond that Z represents the group-CH=CH-, or R10and R11that may be the same or different, have the meanings indicated above for R9or (III) a divalent group-CHR12-CHR13-CH2-, in which R12and R13together they form a bond, Z represents-CH=CH-CH2-, or R12and R13that may be the same or different, have the meanings indicated above for R9,
as well as their additive salts with pharmaceutically acceptable acids or bases, and method of production thereof, pharmaceutical compositions and drug manifesting gipolipedimecescoe and antiatherosclerotic action based on them
< / BR>in which X denotes O or S;R1and R2which may be identical or different, denote hydrogen, (C1-C6)alkyl or (C3-C8)cycloalkyl or R1and R2together with the carbon atom to which they are attached, form a (C3-C8)cycloalkyl;
R3means (C6-C12)aryl, optionally substituted by one or more radicals Y, which may be the same or different;
Y represents halogen;
R4and R5represent hydrogen;
Ar denotes one of the following groups or WITH:
< / BR>T represents hydrogen or (C1-C6)alkyl;T3and T4which may be identical or different, denote (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)allylthiourea;
R6and R7each denotes hydrogen or R6and R7together represent a bond;
Z denotes either (I) the divalent group-CHR9- in which the R11-, in which R10and R11together they form a bond that Z represents the group-CH=CH-, or R10and R11that may be the same or different, have the meanings indicated above for R9or (III) a divalent group-CHR12-CHR13-CH2-, in which R12and R13together they form a bond, Z represents-CH=CH-CH2-, or R12and R13that may be the same or different, have the meanings indicated above for R9,
as well as their additive salts with pharmaceutically acceptable acids or bases, and method of production thereof, pharmaceutical compositions and drug manifesting gipolipedimecescoe and antiatherosclerotic action based on them
New salt // 2193560
The invention relates to a new salt - acid tartrate (R)-3-N,N-dicycloverine-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide, in particular its (2R, 3R)-tartrate and especially acid monohydrate (2R,3R)-tartrate of (R)-3-N,N-dicycloverine-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide, as well as to a method for the specified tartrate salts and pharmaceutical compositions based on it for the treatment and prevention of disorders of the Central nervous system and related medical abuses associated with the activity of the antagonist 5-HT1A-receptor
2,4-xylidide and m-peptide 2-acetylaminofluorene-3 - carboxylic acid, having anticoagulant activity // 2193559
The invention relates to new compounds 2,4-xylidide and m-phenetidine 2-acetylaminofluorene-3-carboxylic acid of General formula 1
,
where Ia) R=2,4-(CH3)2WITH6H3; IB) R=m-C2H5OS6H4that possess anticoagulant activity and can be used in medicine
,where Ia) R=2,4-(CH3)2WITH6H3; IB) R=m-C2H5OS6H4that possess anticoagulant activity and can be used in medicine
The invention relates to a new method for the preparation of 3-N,N-dicycloverine-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide in the form of racemic compounds or R - or S-enantiomers of the formula
< / BR>
< / BR>
< / BR>and their pharmaceutically acceptable salts, as well as intermediate products received and used in the specified way of formulae V-X:
< / BR>
< / BR>
< / BR>
< / BR>
< / BR>The technical result is to simplify the process by eliminating the stage of fluorination, and also due to the fact that this method allows to exclude the receipt of byproduct
< / BR>< / BR>< / BR>and their pharmaceutically acceptable salts, as well as intermediate products received and used in the specified way of formulae V-X:< / BR>< / BR>< / BR>< / BR>< / BR>The technical result is to simplify the process by eliminating the stage of fluorination, and also due to the fact that this method allows to exclude the receipt of byproduct
The invention relates to a new crystalline (-)-3R,4R-TRANS-7-methoxy-2,2-dimethyl-3-phenyl-4-{ 4-[2-(pyrrolidin-1-yl)ethoxy] phenyl} chromane hydrofolate, method thereof, pharmaceutical compositions on the basis and method of reducing or preventing the rarefaction of bone, including the introduction to the patient an effective amount of the specified new connection
The invention relates to new Bermatingen compounds, the United propylenebis communication, General formula I where Ar represents a radical of formula (a) or (b), R1is-OR6or-COR7, R2represents a polyether radical, comprising 1 to 6 carbon atoms and 1 to 3 atoms of oxygen or sulfur, and if in the latter case, R4represents a linear or branched C1-C20alkyl, he is in ortho - or meta-position relative to X-Ar connection, R3represents lower alkyl, or R2or R3taken together form a 6-membered ring, optionally substituted by at least one of the stands and/or optional split the atom of oxygen or sulfur, R4represents H, linear or branched C1-C20alkyl or aryl, R5represents H or-OR8, R6represents H, R7represents H, -OR10or-N(r)r (r) r are H, lower alkyl or taken together with the nitrogen atom form a ring of morpholino, R8represents H or lower alkyl, R10represents H, linear or branched C1-C20alkyl, X represents a divalent radical, which is from right to left or Vice versa has the formula (d), R11Fri carboxylic acid and the optical and geometrical isomers of the above compounds of formula (I)
Substituted germanischer(thio)urea, the method of production thereof and pharmaceutical composition // 2170733
The invention relates to substituted chromalusion (thio)ureas of the formula (I):
< / BR>where R (1) denotes hydrogen, alkyl with 1-4 C-atoms, alkoxy with 1-4 C-atoms, fluorine, chlorine, bromine, iodine, CF3, NH2, NH-alkyl with 1-4 C-atoms, N(alkyl)2with 1-4 C-atoms in the same or different alkyl residues, or S-alkyl with 1-4 C-atoms;
R (2a) denotes hydrogen or alkyl with 1 or 2 C-atoms;
R (2b) and R (2d), which are identical or different, denote hydrogen, alkyl with 1 or 2 C-atoms not substituted phenyl, substituted phenyl, unsubstituted benzyl or substituted phenyl residue, benzyl, and as the substituents in the phenyl residues are up to three identical or different substituents selected from the group consisting of hydrogen, halogen, alkyl with 1 or 2 C-atoms, alkoxyl with 1 or 2 C-atoms;
R (2c) and R (2e), which are identical or different, denote hydrogen or alkyl with 1 or 2 C-atoms;
R (3) denotes hydrogen, alkyl with 1,2,3 or 4 C-atoms, cycloalkyl with 3, 4, 5 or 6 C-atoms in the ring, CH2-cycloalkyl with 3, 4, 5 or 6 C-atoms in the ring, or CF3;
Q represents (CH2)n;
where n = 1 or 2;
Z denotes serousily, selected from the group consisting of hydrogen, halogen, alkyl with 1 or 2 C-atoms, alkoxyl with 1 or 2 C-atoms;
or
A denotes the residue of a saturated or unsaturated lactam of the formula:
< / BR>where B denotes albaniles or alkylene with 3, 4, 5 or 6 C-atoms, which is unsubstituted or substituted by up to three identical or different alkyl groups with 1, 2, 3 or 4 C-atoms;
or
A denotes the residue of a bicyclic system of the formula:
< / BR>
< / BR>
< / BR>
< / BR>and their physiologically acceptable salts
< / BR>where R (1) denotes hydrogen, alkyl with 1-4 C-atoms, alkoxy with 1-4 C-atoms, fluorine, chlorine, bromine, iodine, CF3, NH2, NH-alkyl with 1-4 C-atoms, N(alkyl)2with 1-4 C-atoms in the same or different alkyl residues, or S-alkyl with 1-4 C-atoms;R (2a) denotes hydrogen or alkyl with 1 or 2 C-atoms;
R (2b) and R (2d), which are identical or different, denote hydrogen, alkyl with 1 or 2 C-atoms not substituted phenyl, substituted phenyl, unsubstituted benzyl or substituted phenyl residue, benzyl, and as the substituents in the phenyl residues are up to three identical or different substituents selected from the group consisting of hydrogen, halogen, alkyl with 1 or 2 C-atoms, alkoxyl with 1 or 2 C-atoms;
R (2c) and R (2e), which are identical or different, denote hydrogen or alkyl with 1 or 2 C-atoms;
R (3) denotes hydrogen, alkyl with 1,2,3 or 4 C-atoms, cycloalkyl with 3, 4, 5 or 6 C-atoms in the ring, CH2-cycloalkyl with 3, 4, 5 or 6 C-atoms in the ring, or CF3;
Q represents (CH2)n;
where n = 1 or 2;
Z denotes serousily, selected from the group consisting of hydrogen, halogen, alkyl with 1 or 2 C-atoms, alkoxyl with 1 or 2 C-atoms;
or
A denotes the residue of a saturated or unsaturated lactam of the formula:
< / BR>where B denotes albaniles or alkylene with 3, 4, 5 or 6 C-atoms, which is unsubstituted or substituted by up to three identical or different alkyl groups with 1, 2, 3 or 4 C-atoms;or
A denotes the residue of a bicyclic system of the formula:
< / BR>< / BR>< / BR>< / BR>and their physiologically acceptable salts
The invention relates to bicyclic compounds useful as drugs, the neutralizing effect of glycoprotein IIb/IIIa, to prevent thrombosis
The invention relates to non-steroidal anti-inflammatory drugs, particularly to substituted dihydrobenzofuran and related compounds
